NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these “checkpoint” proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16–17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop.
Contents
Suggested citation:
National Academies of Sciences, Engineering, and Medicine. 2019. Advancing progress in the development of combination cancer therapies with immune checkpoint inhibitors: Proceedings of a workshop. Washington, DC: The National Academies Press. doi: https://doi.org/10.17226/25405.
Digital Object Identifier: https://doi.org/10.17226/25405
Additional copies of this publication are available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.
Printed in the United States of America
- NLM CatalogRelated NLM Catalog Entries
- Advancing Progress in the Development of Combination Cancer Therapies with Immun...Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors
Your browsing activity is empty.
Activity recording is turned off.
See more...